AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Terns Pharmaceuticals Inc (NASDAQ:TERN)
-- USD
0.000 0.000%Sponsored Reports
Loading...
| Previous Close (in USD) | 52.94 |
|---|---|
| Change | 0.000 0.000% |
| 52 W H/L (in USD) | 13.030/3.260 |
| EBITDA (in USD) | -103.549M |
| PE Ratio | -- |
| Volume | -- |
| Diluted Eps TTM | -1.26 |
| Total Assets (in USD) | 268.517M |
|---|---|
| Total Liabilities (in USD) | 13.15M |
| Revenue TTM (in USD) | 1M |
| Cash (in USD) | 79.926M |
| Market Cap (in USD) | 388.063 M |
| Revenue Per Share TTM | 0.035 |
| Gross Profit TTM (in USD) | 1M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Terns Pharmaceuticals Inc
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
1065 East Hillsdale Boulevard, Foster City, CA, United States, 94404
650 525 5535
Employees: 66
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Senthil Vel Sundaram | CEO & Director | 1978 |
| 2. | Dr. Erin Quirk M.D. | Pres & Head of R&D | 1971 |
| 3. | Mr. Seokho Yoon Esq. | COO, Gen. Counsel & Sec. | 1978 |
| 4. | Dr. Weidong Zhong Ph.D. | Co-Founder & Exec. Officer | 1966 |
| 5. | Dr. Mark Joseph Vignola | CFO & Treasurer | 1978 |
| 6. | Dr. Jeffrey R. Jasper Ph.D. | Sr. VP & Head of Research | NA |
| 7. | Ms. Diana Chung | Sr. VP & Chief Devel. Officer | NA |
| 8. | Dr. Kerry Russell M.D., Ph.D. | Chief Medical Officer | NA |
| 9. | Dr. Erin Quirk M.D. | President & Head of Research & Development | 1971 |
| 10. | Mr. Seokho Yoon Esq. | COO, General Counsel & Secretary | 1978 |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.330 0.758% | 43.45 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
0.000 0.000% | 43 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
-7.360 1.604% | 462.17 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+2.010 0.331% | 612.07 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -59.987M | -49.65M | -39.758M | -68.839M | -18.085M |
| Minority Interest | - | 0M | 0.518M | 14.117M | 14.325M |
| Net Income | -60.345M | -50.158M | -40.571M | -68.819M | -17.711M |
| Selling General Administrative | 22.412M | 19.549M | 8.996M | 8.663M | 3.901M |
| Gross Profit | - | 1M | - | - | - |
| Reconciled Depreciation | 1.032M | 0.512M | 0.394M | 0.195M | 0.065M |
| Ebit | -63.061M | -50.372M | -37.025M | -70.197M | -18.455M |
| Ebitda | -62.029M | -49.86M | -36.631M | -70.002M | -18.39M |
| Depreciation And Amortization | 1.032M | 0.512M | 0.394M | 0.195M | 0.065M |
| Operating Income | -62.029M | -49.86M | -37.025M | -70.197M | -18.455M |
| Other Operating Expenses | 62.029M | 50.86M | 37.025M | 70.197M | 18.455M |
| Interest Expense | -2.042M | 0.722M | 2.215M | 1.566M | 0M |
| Tax Provision | 0.358M | 0.508M | 0.813M | -0.02M | -0.067M |
| Interest Income | 2.11M | 0.17M | 0.055M | 1.204M | 0.332M |
| Net Interest Income | 2.11M | 0.17M | 0.055M | 1.204M | 0.332M |
| Income Tax Expense | 0.358M | 0.508M | 0.813M | -0.02M | -0.067M |
| Total Revenue | 0M | 1M | 0M | 0M | 0M |
| Total Operating Expenses | 62.029M | 50.86M | 37.025M | 70.197M | 18.455M |
| Cost Of Revenue | - | - | - | - | - |
| Total Other Income Expense Net | 2.042M | 0.21M | -2.733M | 1.358M | 0.038M |
| Net Income From Continuing Ops | -60.345M | -50.158M | -40.571M | -68.819M | -18.018M |
| Net Income Applicable To Common Shares | -60.345M | -50.158M | -29.352M | -68.611M | -17.711M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 268.517M | 287.026M | 168.07M | 92.29M | 23.904M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 3.992M | 2.071M | 0.948M | 0.331M | 0.461M |
| Total Liab | 13.15M | 10.083M | 7.767M | 23.698M | 19.697M |
| Total Stockholder Equity | 255.367M | 276.943M | 160.303M | 68.592M | 4.207M |
| Other Current Liab | 7.62M | 6.162M | 4.694M | 8.17M | 3.314M |
| Common Stock | 0.006M | 0.005M | 0.003M | - | - |
| Capital Stock | 0.006M | 0.005M | 0.003M | 186.033M | 94.967M |
| Retained Earnings | -332.628M | -242.418M | -182.073M | -131.915M | -91.862M |
| Good Will | - | - | - | - | - |
| Other Assets | 0M | 0.037M | 0.094M | 0.246M | 0.719M |
| Cash | 79.926M | 143.235M | 47.699M | 74.854M | 12.327M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 11.944M | 8.468M | 6.82M | 22.821M | 4.95M |
| Current Deferred Revenue | 1.206M | - | - | 0.836M | - |
| Net Debt | -79.323M | -142.03M | -47.699M | -61.974M | -12.327M |
| Short Term Debt | 0.603M | 0.661M | - | 12.88M | - |
| Short Long Term Debt | - | - | - | 12.88M | - |
| Short Long Term Debt Total | 0.603M | 1.205M | - | 12.88M | - |
| Other Stockholder Equity | 588.008M | 520.178M | 174.641M | 14.598M | 1.208M |
| Property Plant Equipment | - | 0.757M | 1.046M | 1.175M | 0.961M |
| Total Current Assets | 267.432M | 285.185M | 166.93M | 90.869M | 22.224M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | 183.514M | 139.879M | 118.283M | 0M | 7.323M |
| Net Receivables | - | - | - | 12.718M | - |
| Long Term Debt | - | - | - | - | - |
| Inventory | - | - | - | 2.966M | - |
| Accounts Payable | 2.515M | 1.645M | 2.126M | 0.935M | 1.636M |
| Accumulated Other Comprehensive Income | -0.019M | -0.822M | -0.338M | -0.124M | -0.106M |
| Non Currrent Assets Other | 0.056M | 0.037M | 0.094M | 0.246M | 0.719M |
| Non Current Assets Total | 1.085M | 1.841M | 1.14M | 1.421M | 1.68M |
| Capital Lease Obligations | 0.603M | 1.205M | - | - | - |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | -21.997M | -119.356M | 7.277M | -2.956M | -4.532M |
| Total Cashflows From Investing Activities | -22.272M | -119.696M | 6.693M | -3.856M | -4.776M |
| Total Cash From Financing Activities | 167.095M | 134.393M | 85.515M | 0.062M | 99.761M |
| Net Income | -60.345M | -50.158M | -40.571M | -68.819M | -18.018M |
| Change In Cash | 95.536M | -27.155M | 62.479M | -70.147M | 77.017M |
| Begin Period Cash Flow | 47.699M | 74.854M | 12.375M | 82.522M | 5.505M |
| End Period Cash Flow | 143.235M | 47.699M | 74.854M | 12.375M | 82.522M |
| Total Cash From Operating Activities | -49.109M | -41.827M | -29.809M | -66.222M | -18.071M |
| Depreciation | 1.032M | 0.512M | 0.394M | 0.195M | 0.065M |
| Other Cashflows From Investing Activities | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | - | - | - | - | - |
| Sale Purchase Of Stock | 0.243M | - | - | - | - |
| Other Cashflows From Financing Activities | -0.401M | 10.911M | 16.138M | 0.062M | 99.761M |
| Capital Expenditures | 0.275M | 0.34M | 0.584M | 0.9M | 0.244M |
| Change In Working Capital | -1.037M | -1.425M | 5.06M | 1.774M | -0.352M |
| Other Non Cash Items | 0.081M | 0.879M | 2.924M | -0.04M | -0.307M |
| Free Cash Flow | -49.384M | -42.167M | -30.393M | -67.122M | -18.315M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Health Care ETF | 2 years ago | 105224 |
| 2. | Fidelity Small Cap Growth | 2 years ago | 1974407 |
| 3. | Franklin Biotechnology Discv A(acc)USD | 2 years ago | 1582457 |
| 4. | Vanguard Total Stock Mkt Idx Inv | 2 years ago | 1293066 |
| 5. | iShares Russell 2000 ETF | 2 years ago | 1003192 |
| 6. | Franklin Biotechnology Discovery A | 2 years ago | 799126 |
| 7. | Fidelity Small Cap Growth K6 | 2 years ago | 732810 |
| 8. | HBM Healthcare Investments AG Ord | 2 years ago | 671975 |
| 9. | Vanguard Institutional Extnd Mkt Idx Tr | 2 years ago | 532520 |
| 10. | Fidelity Small Cap Index | 2 years ago | 438096 |
| 11. | iShares Biotechnology ETF | 2 years ago | 277367 |
| 12. | State St Russell Sm/Mid Cp® Indx NL Cl C | 2 years ago | 271100 |
| 13. | iShares Russell 2000 Growth ETF | 2 years ago | 238996 |
| 14. | Russell Inv Tax-Managed US Mid&Sm Cap S | 2 years ago | 229157 |
| 15. | Fidelity Extended Market Index | 2 years ago | 204341 |
| 16. | Vanguard Russell 2000 ETF | 2 years ago | 161150 |
| 17. | State St Russell Sm Cap® Indx SL Cl I | 2 years ago | 158000 |
| 18. | Russell Inv US Small Cap Equity E | 2 years ago | 136505 |
| 19. | iShares Russell 2000 Value ETF | 2 years ago | 128632 |
| 20. | NT R2000 Index Fund - NL | 2 years ago | 120698 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Orbimed Advisors, LLC | 2 years ago | 7619135 |
| 2. | Vivo Capital, LLC | 2 years ago | 6657992 |
| 3. | Deep Track Capital, LP | 2 years ago | 6100000 |
| 4. | Millennium Management LLC | 2 years ago | 3432792 |
| 5. | BlackRock Inc | 2 years ago | 3408978 |
| 6. | FMR Inc | 2 years ago | 2990402 |
| 7. | Franklin Resources Inc | 2 years ago | 2307834 |
| 8. | Vanguard Group Inc | 2 years ago | 2199006 |
| 9. | Fairmount Funds Management LLC | 2 years ago | 2040000 |
| 10. | HHG PLC | 2 years ago | 2003263 |
| 11. | Morgan Stanley - Brokerage Accounts | 2 years ago | 1724706 |
| 12. | Suvretta Capital Management, LLC | 2 years ago | 1363675 |
| 13. | Great Point Partners LLC | 2 years ago | 1309975 |
| 14. | Driehaus Capital Management LLC | 2 years ago | 1083905 |
| 15. | State Street Corporation | 2 years ago | 886879 |
| 16. | Adage Capital Partners Gp LLC | 2 years ago | 850000 |
| 17. | Geode Capital Management, LLC | 2 years ago | 840459 |
| 18. | Decheng Capital LLC | 2 years ago | 714285 |
| 19. | Octagon Capital Advisors LP | 2 years ago | 625000 |
| 20. | Longwood Capital Partners LLC | 2 years ago | 465079 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...